ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2006
Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- HIV-1 Tat reduces apical dendritic spine density throughout the trisynaptic pathway in the hippocampus of male transgenic mice.Neuroscience letters · 2022Article
- Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.Frontiers in immunology · 2021Article
- HIV gp120-induced neuroinflammation potentiates NMDA receptors to overcome basal suppression of inhibitory synapses by p38 MAPK.Journal of neurochemistry · 2019Article
- Scaling Synapses in the Presence of HIV.Neurochemical research · 2019Review
- Sensitization of enteric neurons to morphine by HIV-1 Tat protein.Neurogastroenterology and motility · 2015Article
- GSK3β-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity.Molecular and cellular neurosciences · 2015Article
- PACAP27 is protective against tat-induced neurotoxicity.Journal of molecular neuroscience : MN · 2014Article
- Morphine enhances HIV-1SF162-mediated neuron death and delays recovery of injured neurites.PloS one · 2014Article
- D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Article
- Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex.Journal of Alzheimer's disease : JAD · 2011Article
- Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2010Article
- Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2010Review
- Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons.The American journal of pathology · 2010Article
- HIV and SIV induce alterations in CNS CaMKII expression and activation: a potential mechanism for cognitive impairment.The American journal of pathology · 2010Article
- Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE.Laboratory investigation; a journal of technical methods and pathology · 2010Article
- Persistent hijacking of brain proteasomes in HIV-associated dementia.The American journal of pathology · 2010Article
- Neuroprotective activities of CEP-1347 in models of neuroAIDS.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2009Article
- The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Loss of synaptic integrity and function appears to underlie neurologic deficits in patients with HIV-1-associated dementia (HAD) and other chronic neurodegenerative diseases. Because synaptic injury often long precedes neuronal death and surviving neurons possess a remarkable capacity for synaptic repair and functional recovery, we hypothesize that therapeutic intervention to protect synapses has great potential to improve neurologic function in HAD and other diseases. We discuss findings from both HAD and Alzheimer's disease to demonstrate that the disruption of synaptic structure and function that can occur during excitotoxic injury and neuroinflammation represents a likely substrate for neurologic deficits. Based on available evidence, we provide a rationale for future studies aimed at identifying molecular targets for synaptic protection in neurodegenerative disease. Whereas patients with HAD beginning antiretroviral therapy have shown reversal of neurologic symptoms that is unique for patients with chronic neurodegenerative conditions, we propose that the potential for such reversal is not unique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.